Ypsomed Holding AG (YPSN.SW) stock: Winston Score, insiders and Congress trades

Ypsomed is a Swiss company that makes drug delivery devices — the pens, auto-injectors, and wearable pumps that patients use to inject medications like insulin or GLP-1 drugs at home. Its main customers are large pharmaceutical companies, which hire Ypsomed to design and manufacture the physical devices that come bundled with their drugs. The company also sells its own branded insulin pumps directly to people with diabetes under the mylife brand. Ypsomed earns money by selling devices and components to pharma partners under long-term supply contracts, and by selling its own diabetes products directly to patients and clinics. It operates primarily in Europe, with growing reach in the US and Asia, and generates roughly $700–800 million in annual revenue. Its competitive edge comes from deep engineering expertise and the high switching costs pharma companies face once a device is approved alongside a specific drug. The biggest growth driver is rising demand for GLP-1 injection devices, though heavy reliance on a small number of large pharma customers remains a key concentration risk.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-11.